Skip to Content


In the US, Carmustine (carmustine systemic) is a member of the drug class alkylating agents and is used to treat Brain Tumor, Glioblastoma Multiforme, Hodgkin's Lymphoma, Malignant Glioma, Multiple Myeloma and Non-Hodgkin's Lymphoma.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Cytostatic alkylating agent

Chemical Name

Urea, N,N'-bis(2-chloroetyl)-N-nitroso-

Foreign Names

  • Carmustinum (Latin)
  • Carmustin (German)
  • Carmustine (French)
  • Carmustina (Spanish)

Generic Names

  • Carmustina (OS: DCIT)
  • Carmustine (OS: BAN, USAN, DCF, JAN)
  • BCNU (IS)
  • NSC 409962 (IS)
  • SK 27702 (IS)
  • Carmustin (PH: Ph. Eur. 8)
  • Carmustine (PH: BP 2016, Ph. Eur. 8, USP 38)
  • Carmustinum (PH: Ph. Eur. 8)

Brand Names

  • Becenun
    Bristol-Myers Squibb, Brazil
  • BiCNU
    Bristol-Myers Squibb, Australia; Bristol-Myers Squibb, Bulgaria; Bristol-Myers Squibb, Canada; Bristol-Myers Squibb, Czech Republic; Bristol-Myers Squibb, Egypt; Bristol-Myers Squibb, Lebanon; Bristol-Myers Squibb, New Zealand; Bristol-Myers Squibb, Tunisia; Bristol-Myers Squibb, Taiwan; CN Unifarm, Romania; CSP, France; Heritage, United States; Merck Serono, Argentina; Salus, Slovenia
  • Carmubris
    Emcure Pharma UK, Austria
  • Gliadel
    Arbor Pharmaceuticals, United States; Archimedes Pharma, Germany; Archimedes Pharma France, France; Eisai, United Kingdom; Eisai, Ireland; Eisai, Israel; Eisai, Italy; Eisai, Malaysia; Eisai Farmaceutica, Spain; MGI, Netherlands; MGI Pharma, Greece; Nobelpharma, Japan; Orphan, Australia; Pharmaplan, South Africa; Sanofi-Aventis, Portugal


BANBritish Approved Name
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.